

Curriculum Vitae – Professor Geoffrey Ian Hackett

Holly Cottage

Fisherwick Rd.

Lichfield Staffordshire WS14 9JL

Tel: 01543 432757 / Mobile: 07702 345667

Email: hackettgeoff@gmail.com

DOB 5th October 1950

GMC 1647097

MDU 110064B

Qualifications

MB. BS. Kings College Hospital, London UK. 1968 to 1973

MRCPI. Dublin, Ireland 1978

MRCGP. London England 1980

MD. Keele University, Keele, Staffordshire, 2000

FRCP Dublin Ireland March 2007.

Fellow of the Institute of Sports Medicine, London. UK 1993

FECSM. Fellow of the European College of Sexual Medicine 2013.

Training in GCP for Clinical Trials. Madrid May 2013.

Prizes.

Zorgniotti-Newman prize for Clinical Research 2012 (ISSM Chicago) - Testosterone improves sexual function and Quality of Life in men with type 2 diabetes,

Charles Oliver Hawthorne Research Award in Medicine - BMA London 1986 The Duke of Edinburgh Prize in Sports Medicine 1993 London

Current Appointments.

1. **Consultant in Urology / Andrology (2 Sessions) Good Hope Hospital, Sutton Coldfield UK and Spire Hospital, Little Aston. 1994-2019**
2. **Professor of Sexual Medicine, Aston University Medical School, Birmingham October 2017**

--

3. Regular Scientific Reviewer for BMJ, JSM, IJIR, and IJCP, Andrology, Urology.

4. Medical Adviser to European Golf Tour 2010 –

5. Member of Executive Committee of the ESSM (2016- 2018)

6. Private Sexual Medicine Practice Spire Little Aston Hospital 2014 –

8. Committee member of Primary Care Testosterone Advisory Group. 2016-

9. Past President of BSSM 2010-2012.

Previous Appointments

2012-2016. Visiting Professor in Diabetes and Men's Health at Hertfordshire and Bedfordshire University (2 sessions)

2016-2018. ESSM Committee Member.

Recent Research Publications

Over 60 studies in Sexual Medicine – ED and Hypogonadism, PE, FSD. 1996-2015

The RYHME registry (Register of Hypogonadism in Men, 2009-2014. 50 Patients

The BLAST study and long- term extension 2009-2015

Hackett G, Cole N, Bhartia M, Wilkinson P, Raju J, Wilkinson P. Testosterone Replacement Therapy Improves Metabolic Parameters in Hypogonadal Men with Type 2 Diabetes but not in Men with Coexisting Depression: The BLAST Study. *J Sex Med* 2014; 11(3): 840-56.

Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum Testosterone, Testosterone Replacement Therapy and All- cause Mortality in men with Type 3 Diabetes: Retrospective Consideration of the impact of PDE5 Inhibitors and Statins. *Int J Clin Pract.* 2016; 70(3):244-53

Hackett G, Cole N, Bhartia M et al. Testosterone Replacement Therapy with Long-Acting Testosterone Undecanoate Improves Sexual Function and Quality-of-Life Parameters vs. Placebo in a Population of Men with Type 2 Diabetes *JSM.* 2013 Volume 10, Issue 6, Pages 1612–1627

Hackett G, Cole N, Saghir A. et al Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study. *BJUI* 118; 5 November 2016 Pages 804–813

Anderson S, Hutchings DC, Woodward M, Hackett G, Kirby M, Heald A. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality *Heart* doi: 10.1136/heartjnl-2015-309223.

Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5Inhibitors and statins. *Int J Clin Pract* 2016; 70(3): 244-253.

Hackett G, Jones PW, Strange RC & Ramachandran S. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age- related mortality in diabetes. *World J Diabetes* 2017; 8(3): 104-111.

Hackett G, The Graham Jackson Memorial Lecture, “The man who knew too much”. *Sexual Medicine Reviews* March 2007 1-10.

Hackett G, Testosterone Therapy and Cardiovascular Risk in Oxford Textbook of Urological Surgery. Chapter 7:12. 2017 ISBN: 9780199659579

Hackett G, Erectile Dysfunction, Testosterone, and Cardiovascular Disease. *European Textbook of Cardiology* 2017

Hackett G, Kirby M, Jones TH et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency 2017 *J Sex Med* 2017;14:1504e1523

Hackett G, Kirby M, Wylie K et al. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men – 2017. *J Sex Med* 2018 Apr;15(4):430-457. doi: 10.1016/j.jsxm.2018.01.023. Epub 2018 Mar 14.

Hackett G, Jones P et al. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes . *World J Diabetes* 2017 March 15; 8(3): 104-111 DOI: 10.4239/wjd.v8.i3.104

Ramachandran S, Hackett G et al. Managing Clinical Heterogeneity: An Argument for Benefit-Based Action Limits. *Journal of Engineering and Science in Medical Diagnostics and Therapy* AUGUST 2018, Vol. 1 / 034701-1

Hackett G. Type 2 Diabetes and Testosterone Therapy . *World Journal of Men’s Health*. pISSN: 2287-4208 / eISSN: 2287-4690 *World J Men’s Health* Published online M D, 2018
<https://doi.org/10.5534/wjmh.180027>

Hackett G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. <https://doi.org/10.1016/j.sxmr.2018.12.004>

Hackett G. Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor? pISSN: 2287-4208 / eISSN: 2287-4690 *World J Mens Health* Published online M D, 2020
<https://doi.org/10.5534/wjmh.200027>

Ramachandran S, Hackett G, Strange R. Testosterone replacement therapy: Pre-treatment sex hormone binding globulin levels and age may identify clinical subgroups. *Andrology* 2020
<https://doi.org/10.1111/andr.12813>

Stedman M, Heald A, Hackett G et al. The treatment rate of erectile dysfunction (ED) in younger men with Type 2 Diabetes is up to 4 times higher than the equivalent non-diabetes population 19 May 2020.

<https://doi.org/10.1111/ijcp.13538>

G. Hackett

Prof G I Hackett 7th June 2020